(Q80066093)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17396105%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

Imatinib for the treatment of rheumatic diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17396105%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

1 reference

Ricardo T Paniagua

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17396105%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

William H Robinson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17396105%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17396105%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Rheumatology

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17396105%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17396105%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17396105%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

190-191

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17396105%20AND%20SRC:MED&resulttype=core&format=json

Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0465

7 January 2021

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0465

7 January 2021

Reversal of experimental pulmonary hypertension by PDGF inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0465

7 January 2021

Imatinib for the treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0465

7 January 2021

Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0465

7 January 2021

Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0465

7 January 2021

Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0465

7 January 2021

Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0465

7 January 2021

Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0465

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0465

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0465

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17396105%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference